CDX2

CDX2 (Caudal-type Homeobox 2) is a protein that acts as a master switch for intestinal cell identity. Pathologists detect it with immunohistochemistry staining on biopsy tissue, where strong nuclear staining typically signals that a tumor originated in the gastrointestinal tract, most often the colon. It is used mainly as a tool to tell different cancers apart, not as a marker of asbestos exposure itself.

Origin

CDX2 was identified in the 1990s as the human homolog of the mouse Cdx2 gene, part of the caudal-related homeobox family first characterized in Drosophila. The name reflects its role in patterning the caudal (tail-end) embryo and, later in life, in maintaining the lining of the intestine.

Significance in Asbestos Context

CDX2 matters to asbestos patients primarily during the diagnostic work-up, not as an asbestos biomarker. When a tumor is found in the abdomen or chest, pathologists must distinguish peritoneal mesothelioma from metastatic colon or other gastrointestinal cancers, which can look similar under the microscope. Mesothelioma is almost always CDX2-negative, while colorectal adenocarcinoma is usually strongly CDX2-positive, so this stain helps confirm a mesothelioma diagnosis and rule out look-alikes. Getting this distinction right is critical, because mesothelioma is the disease specifically linked to asbestos exposure and is central to any asbestos claim.

Example Sentence

The pathology report noted that the tumor cells were CDX2-negative and calretinin-positive, supporting a diagnosis of peritoneal mesothelioma rather than metastatic colon cancer.

Related Terms

Immunohistochemistry, Calretinin, WT-1, Peritoneal Mesothelioma, Differential Diagnosis, Adenocarcinoma

Notes

• Ask your oncologist or pathologist which IHC markers were used to confirm your diagnosis; a complete mesothelioma panel typically includes CDX2 (negative), along with calretinin, WT-1, and cytokeratin 5/6 (positive).
• If your tumor is in the abdomen, the CDX2 result is especially important for distinguishing peritoneal mesothelioma from gastrointestinal cancers. Request that this be addressed explicitly in the pathology report.
• Preserve copies of the full pathology and IHC reports; these documents are central evidence in any asbestos claim and may be reviewed by a second pathologist for confirmation.
• Consider asking whether a second-opinion review at a mesothelioma specialty center (such as an NCI-designated cancer center) is warranted before treatment decisions are finalized.